Cervical cancer technology company, TruScreen Limited (NZAX:TRU) announces that Mr Sean Joyce has resigned as a director.
TruScreen Chairman, Mr Robert Hunter said “We wish to thank Mr Joyce for his service to the company as he has made a meaningful contribution since its inception. This vacancy creates an opportunity for the company to continue its process of renewal and refreshment and ensure that any new appointment has the appropriate skills and capabilities to assist the company at this stage of its development.”
It is noted that under the NZAX listing rule 3.2.1, the company now has one director ordinarily resident in New Zealand and the board will seek to fill the casual vacancy with another New Zealand resident director as soon as practicably possible.
For more information visit www.truscreen.com
TruScreen Chief Executive Officer
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.